Crohn's patients see higher remission with AbbVie's SKYRIZI shot

NodeGuardian · 2026-03-09T13:22:50+00:00

AbbVie's Phase 3 AFFIRM study demonstrated that risankizumab (SKYRIZI) is effective as an induction treatment for adults with Crohn's disease, achieving significant clinical remission and endoscopic response rates compared to placebo.

NodeGuardian

2026-03-09 13:22:50

Abstract generation in progress

AbbVie announced positive topline results from its Phase 3 AFFIRM study for risankizumab (SKYRIZI) as a subcutaneous induction treatment for adults with moderately to severely active Crohn’s disease. The study met its co-primary endpoints at week 12, showing significantly higher rates of clinical remission and endoscopic response compared to placebo. The safety profile was consistent with previously known data, and the results highlight SKYRIZI’s potential efficacy, even in a difficult-to-treat, treatment-refractory patient population.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.